The Alzheimer’s Therapeutics Market is expected to reach USD 9.32 Billion by 2028, according to a new report by Reports and Data. This can be mainly associated with the growing pipeline drug development, investment in biomarkers for drug development which are expected to further accelerate the market growth globally. Based on statistics, increase in advanced diagnostics for early detection, along with more specific drug development, and emerging innovative diagnostics technologies are also some of the factors that are also helping to grow the size of the global market.

Alzheimer's disease (AD) is the most usual cause of dementia worldwide. The study of this disease is multifactorial, and pathophysiology is also complicated. According to several types of research, an exponential rise in the number of cases of AD, highlighting the need for developing an effective treatment. AD also imposes a tremendous emotional and financial trouble to the patient's family and society. The disease has been studied for more than a century, but memantine and acetylcholinesterase inhibitors are the only drugs currently recommended for its management. These drugs provide significant improvement alone but do less to change the disease process. The significant penetration into the molecular and cellular pathomechanism in AD over the previous few decades has given us considerable progress in the understanding of the disease. Several novel strategies that seek to revise the disease process have been developed. The notable developments in this direction are the tau-based and amyloid therapeutics, which could hold the key to treatment of AD shortly.

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.reportsanddata.com/download-free-sample/1364

North America market for Alzheimer’s Therapeutics accounts for the largest share of 29.30% in 2020. Due to the presence of advanced healthcare facilities and infrastructure in developed countries, such as the U.S. Moreover, the high buying power for expensive drugs and compensation policies are the drivers projected to promote the market demand.

Further key findings from the report suggest

• Alzheimer’s is a kind of dementia, which affects thinking, behavior, and memory of the patient. The progression of the disease is moderate, and it diminishes neurons associated with the learning part of the cerebrum. It is the most common and the most significant form of dementia (more than 60%), which can be observed in people of age between 65 and over.
• Many researches are being conducted to promote treatment concentrated on the role of beta-amyloid in Alzheimer’s disease. The artificial joints are designed to replicate the movement of a typical, healthy joint.
• Cholinesterase inhibitors therapeutics accounts for the largest share of 38.85% in 2020. It can also improve neuropsychiatric symptoms, such as depression or agitation.
• Generally prescribed cholinesterase inhibitors are galantamine (Razadyne), donepezil (Aricept), and rivastigmine (Exelon).
• CT scans often can reveal specific changes that are characteristic of Alzheimer's disease in its succeeding stages. These changes include widened indentations in the tissues, a reduction in the size of the brain (atrophy), and expansion of the fluid-filled chambers called cerebral ventricles.
• CT scan diagnostic type is expected to reach USD 4.95 billion by 2028. CT (computed tomography) scan is a procedure in which various X-rays of the body are examined from several angles in a short period.
• CT imaging generates the images by estimating how quickly the body and organs receive the X-rays.
• The pipeline drugs sector accounts for a market share of 31.15% in 2020. The presence and advancement of pipeline drugs, such as LMTX by TauRx Pharmaceuticals Ltd., are anticipated to have a substantial positive impact on the growth of this industry.
• This drug is under Phase 3 clinical trial currently to assess its safety and efficacy in the therapy of mild-to-moderate Alzheimer’s disease.
• The result of the clinical trial is supposed to be announced in 2016. Other pipeline drugs include verubecestat by Merck. Co., Inc.; crenezumab by AC Immune SA; and idalopirdine (Lu AE58054) by Lundbeck A/S, which are in Phase 3 of a clinical trial and are expected to be launched over the next 6 years.
• Many organizations included in this activity are Alzheimer’s Association, the National Institute of Health (NIH), and the Florida Department of Health. The NIH contributed around USD 589 million on research projects for AD in 2015.
• Recently, a new proposal known as Alzheimer’s Combination Therapy Opportunities was launched in collaboration with Alzheimer’s Association, Alzheimer’s Drug Discovery Foundation, and Alzheimer’s Society UK. This proposal is expected to provide growth opportunities for the market.
• The proposal involves a combination of repurposed or repositioned drugs that have the ability to slow down the progression of AD.

Competitive Outlook of the Global Alzheimer's Therapeutics Market

The globla Alzheimer's Therapeutics market study focuses on the revenue growth trajectories of the leading companies in this market. This section of the report throws light on the highly competitive landscape of the Alzheimer's Therapeutics market, pointing out the major players. The report further discusses the strategic initiatives undertaken by each of these market players, including mergers acquisitions, collaborations, joint ventures, new product launches, new business deals, and technological innovations.

Top Companies Profiled in the Report:

Eli Lilly and Company, Daiichi Sankyo Hoffmann-La Roche Ltd, Pfizer, Inc., Eisai Co., Ltd., Novartis AG, H. Lundbeck A/S, TauRx Therapeutics Ltd, Forest Laboratories, Inc., AC Immun, Johnson Johnson, TauRx Pharmaceuticals Ltd, VTV Therapeutics

Inquiry Before Buying @ https://www.reportsanddata.com/inquiry-before-buying/1364

The report is inclusive of product type outlook, application spectrum, end-use outlook, technology landscape, regional market analysis, and competitive overview.

Alzheimer's Therapeutics Market Segmentation:

Therapeutics  Outlook (Revenue, USD Million; 2020-2028)

• Cholinesterase inhibitors
• Pipeline Drugs
• NMDA receptor antagonist

End User Outlook (Revenue, USD Million; 2020-2028)

• Hospital Pharmacies
• Retail Pharmacies
• e-Commerce

Diagnostics Type  Outlook (Revenue, USD Million; 2020-2028)

• Computed tomography (CT) scan
• Magnetic resonance imaging (MRI)
• Lumbar puncture test
• Electroencephalography (EEG)
• Others

Geographic Segment Covered in the Report:

The Alzheimer's Therapeutics report provides information about the market area, which is further subdivided into sub-regions and countries/regions. In addition to the market share in each country and sub-region, this chapter of this report also contains information on profit opportunities. This chapter of the report mentions the market share and growth rate of each region, country, and sub-region during the estimated period.

• North America (USA and Canada)
  
  
• Europe (UK, Germany, France and the rest of Europe)
  
  
• Asia Pacific (China, Japan, India, and the rest of the Asia Pacific region)
  
  
• Latin America (Brazil, Mexico, and the rest of Latin America)
  
  
• Middle East and Africa (GCC and rest of the Middle East and Africa)

Request customization of the report @ https://www.reportsanddata.com/request-customization-form/1364

Thank you for reading our report. Customization of this report is available as per the client’s requirements. Please connect with us to know more about the report and our team will ensure you get the report tailored according to your needs.

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, TouchPoints, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provide our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W

Head of Business Development

Reports and Data | Web: www.reportsanddata.com

Direct Line: +1-212-710-1370

E-mail: sales@reportsanddata.com